NEJM: Bimekizumab vs. Adalimumab in the treatment of moderate to severe plaque psoriasis

The pro-inflammatory cytokines interleukin 12 and tumor necrosis factor (TNF) play a role in the pathogenesis of psoriasis, while interleukin 17 and interleukin 23 are also involved in the pathogenesis of psoriasis, but the current TNF inhibitor is still silver Adalimumab is the main treatment method for scoria.

Patients with moderate to severe plaque psoriasis were randomized to receive 320 mg Bimekizumab every 4 weeks for 56 weeks, 320 mg Bimekizumab every 4 weeks for 16 weeks, and then adjusted to 320 mg Bimekizumab every 8 weeks for 56 weeks or 40 mg Ada every 2 weeks Lumumab treatment lasted for 24 weeks, followed by 320 mg Bimekizumab every 4 weeks for 56 weeks.

478 patients participated in the study, 158 in the Bimekizumab treatment group every 4 weeks, 161 in the Bimekizumab treatment group and 159 in the adalimumab treatment group every 4 weeks and then 8 weeks.

Studies believe that the therapeutic effect of Bimekizumab on moderate to severe plaque psoriasis is due to adalimumab, but the risk of diarrhea and infection is increased .

Richard B.